Back

ResearchAndMarkets adds ALPN-303 sales forecast report through 2034

Verifying
  • ResearchAndMarkets.com added a report assessing ALPN-303 across autoimmune and kidney disease indications.
  • The report forecasts ALPN-303 sales from 2020 through 2034 across seven major markets.
  • Vertex Pharmaceuticals announced a USD 4.9 billion Alpine Immune Sciences acquisition agreement in April 2024.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.